Typewriter Therapeutics
Typewriter Therapeutics Raises $56M Series A for In Vivo CAR T Medicines
Typewriter Therapeutics announced $56M in Series A financing on September 2, 2026. Typewriter Therapeutics emerged from stealth with a $56 million Series A led by AN Venture Partners and RA Capital Management to develop in vivo CAR T medicines.
Round details
The financing includes backing from AN Venture Partners, RA Capital Management, ANRI, Gemseki, SBI US Gateway Fund. The company did not publish a valuation with the announcement.
- Round: Series A
- Capital announced: $56M
How the company plans to use the capital
Typewriter Therapeutics said the financing will let it build on its proof-of-concept results in humanized mouse models and establish its first in vivo CAR T development candidate. The release also said the company’s first non-human primate studies are planned for late 2026.
Why this matters for GTM teams
The round was co-led by AN Venture Partners and RA Capital Management for a company whose approach uses lipid nanoparticle-delivered RNA to insert a gene into a safe-harbor site in T cells. The company said its first non-human primate studies are planned for late 2026.
Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.
Source and methodology
This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.
Primary source: Typewriter Therapeutics Series A announcement.
Company Info
Investors (5)
Share
Related Reports
Wabi Raises $55M at $1.25B Valuation in IVP-Led Funding
Wabi announced $55 million in funding led by IVP at a $1.25 billion valuation, which it said will support continued product development and expansion.
StimCardio Raises $30M Series A for Wearable AF Therapeutic
StimCardio announced the closing of an oversubscribed $30 million Series A led by Metis Medtech, expected to fund the company through its planned NeuroPulse 2 pivotal study and preparation for an FDA De Novo submission.
Casap Raises $56M Series B for AI Agents in Financial Services
Casap raised a $56 million Series B led by Base10 Partners, with Experian and Synchrony participating, to advance its AI agent platform for financial services.
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started


